Key result
Nesiritide improves hemodynamics and symptoms in decompensated heart failure, but lacks outcome data demonstrating superiority over conventional therapy.
Why the study?
Does nesiritide improve symptoms and hemodynamics in patients with decompensated heart failure?
Does nesiritide improve symptoms and hemodynamics in patients with decompensated heart failure?
Nesiritide is an effective intravenous vasodilator that improves hemodynamics and symptoms in decompensated heart failure without requiring hemodynamic monitoring, though robust outcome data demonstrating superiority over conventional therapy are lacking.
Answers are grounded in this paper and cite their sources.
May support rapid hemodynamic and symptom relief in acute HF; leaves open superiority on outcomes versus conventional therapy.
Nesiritide is a human brain type natriuretic peptide. The addition of nesiritide, a balanced venous and arterial dilator for the treatment of decompensated heart failure, is the first intravenous (IV) therapy developed in the past decade. Nesiritide binds to receptors in the kidneys, vasculature, and other organs to produce vasodilation and natriuresis. These effects act to reduce ventricular filling pressures and rapidly improve symptoms of heart failure. Nesiritide reduces pulmonary capillary wedge pressure and pulmonary artery pressure, improves the cardiac index, and has minimal effects on heart rate. The limiting side effect of nesiritide is dose-related hypotension. It should not be used in patients with suspected or measured low filling pressures or patients with baseline hypotension. Current literature supports the efficacy of nesiritide; however, there are very few outcome data demonstrating the superiority of nesiritide over conventional therapy. Because this vasodilator does not require hemodynamic monitoring for utilization, it may be an attractive agent for a defined group of patients with decompensated heart failure.
No takes yet. Share an insight, caveat, or question.
Michael Militello (2002) conducted a review in Decompensated heart failure. Nesiritide vs. Conventional therapy was evaluated. Nesiritide improves hemodynamics and symptoms in decompensated heart failure, but lacks outcome data demonstrating superiority over conventional therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: